BNP Screening for PAH in Scleroderma PDF Print E-mail
Tuesday, 24 July 2012 19:41
An elevated level of N-terminal pro-brain natriuretic peptide (NT-proBNP) has a high sensitivity and specificity for pulmonary arterial hypertension in patients with systemic sclerosis (SSc-PAH), Australian rheumatologists and cardiologists have suggested.

They investigated a total of 94 patients with systemic sclerosis in four groups: one with SSc-PAH confirmed by right heart catheterisation, another considered at high risk because of findings on trans-thoracic echocardiography, a group with interstitial lung disease, and a group with no cardiopulmonary complications.

“NT-proBNP was highest in the PAH group compared with the other groups, and higher in the risk group compared with controls,” they said.

The marker was positively correlated with systolic and mean pulmonary artery pressure, pulmonary vascular resistance and mean right atrial pressure.

Further analysis defined thresholds for NT-proBNP and/or results on carbon monoxide pulmonary diffusion tests that should prompt investigation for possible PAH, for example with echocardiography, high-resolution CT, 6-minute walk test, and definitive right heart catheterisation when indicated.

PAH accounted for about 30% of deaths related to systemic sclerosis, the researchers said. In its earliest stages, patients were often asymptomatic or minimally symptomatic but early detection and treatment could delay progression and improve survival.

Annual echocardiography was recommended to screen for early PAH, but this strategy had limitations including technical challenges, insufficient reliability in the presence of coexisting lung disease, poor acoustic windows in some patients, the need for expertise, and issues of cost and resource allocation.

NT-proBNP was released by cardiac myocytes in response to increased ventricular wall stress. The blood test was now widely available given its importance in the diagnosis, prognosis and risk stratification of congestive cardiac failure, they said.

Source: James, T. (2012), "BNP screening for pulmonary arterial hypertension in systemic sclerosis"; Rheumatology Update; original article can be viewed here.

 
More articles :

» Scleroderma Foundation Medical Advisory Board Offers Consensus On Gleevec

® (imatinib mesylate, Novartis) is approved in the United States for the treatment of certain forms leukemias and solid tumors. The recent discovery that Gleevec® inhibits important cellular enzymes that control fibrosis led to studies to evaluate...

» Predictors Of Interstitial Lung Disease In Early Systemic Sclerosis

Introduction: The objective of the present study was to examine the association of baseline demographic andclinical characteristics with sequentially obtained measurements of forced vital capacity (FVC), expressed as apercentage of the predicted...

» arGentis Continues To Expand

But arGentis grew its drug-development pipeline this month with the acquisition of the rights to a rheumatoid arthritis therapy from the - the terms of which, were not disclosed. The treatment was developed at the University of Tennessee Health...

» UC Davis Researchers Win Prestigious NIH Awards

The National Institutes of Health on Tuesday named three UC Davis researchers recipients of highly competitive awards designed to encourage innovative, high-risk research and accelerate the translation of science into improved health.Reflecting the...

» Juvenile Scleroderma Progression Similar To Adult Onset

The pattern and course of disease in patients who develop systemic sclerosis in childhood or adolescence is similar to that in patients who develop the disease as adults, data from Europe has shown.There were 60 patients among 5,000 included in the...

» The Scleroderma Foundation Announces June as 'Scleroderma Awareness Month'

Dedicated to serving the needs of those whose lives have been impacted by scleroderma through its three-fold mission of support, education and research, the is proud to announce June as "Scleroderma Awareness Month."  During June Scleroderma...